(0.31%) 5 115.84 points
(0.30%) 38 356 points
(0.35%) 15 984 points
(-0.99%) $83.02
(5.36%) $2.03
(0.29%) $2 354.10
(0.36%) $27.63
(4.11%) $960.00
(-0.28%) $0.932
(-0.45%) $10.98
(-0.59%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.08%
@ $21.78
発行日: 15 2月 2024 @ 03:47
リターン: 9.99%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: -1.94 %
Live Chart Being Loaded With Signals
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics...
Stats | |
---|---|
本日の出来高 | 69 426.00 |
平均出来高 | 396 116 |
時価総額 | 972.19M |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-1.260 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.71 |
ATR14 | $0.0710 (0.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 24 000 | Share Option (Right to Buy) |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
INSIDER POWER |
---|
72.48 |
Last 94 transactions |
Buy: 1 498 500 | Sell: 230 741 |
ボリューム 相関
Bicycle Therapeutics PLC 相関
10 最も負の相関 | |
---|---|
INTA | -0.972 |
GXII | -0.97 |
TETC | -0.968 |
CRZN | -0.963 |
AGGR | -0.963 |
MSDAU | -0.962 |
TBSAU | -0.962 |
LDHA | -0.962 |
HERA | -0.961 |
MSDA | -0.961 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Bicycle Therapeutics PLC 相関 - 通貨/商品
Bicycle Therapeutics PLC 財務諸表
Annual | 2023 |
収益: | $26.98M |
総利益: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2023 |
収益: | $26.98M |
総利益: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2022 |
収益: | $14.46M |
総利益: | $10.78M (74.51 %) |
EPS: | $-3.80 |
FY | 2021 |
収益: | $11.70M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Bicycle Therapeutics PLC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。